General surgical intervention with a moderate risk of venous thromboembolism in surgery day is introduced in antifactor-Ha 2 hours before or 6 hours after surgery. In the days that followed introduced by antifactor Ha every 24 hours. To complete this dosing regimen is necessary to use the drug equipose. Orthopaedic surgery with high risk of venous thromboembolism in surgery day administered antifactor before or after 6 hours after surgery. In the days that followed introduced . Preventive treatment should be carried out by a physician for at least 7-10 days, and after surgery until the reduce the risk of thromboembolic complications or to complete patient mobilization.
Thromboembolism prophylaxis in patients without surgery The recommended daily intake of sodium bemiparin -. 2500 or 3500 IU, depending on the degree of risk of thromboembolism Prophylactic treatment should be carried out by a physician during the risk period of thromboembolism, or to complete patient mobilization. Secondary prevention of recurrence of venous thromboembolism in patients with deep vein thrombosis and transient risk factors sodium Bemiparin can be administered in a daily dose of to patients receiving anticoagulant therapy against deep vein thrombosis with pulmonary embolism or without, as a therapeutic alternative to oral anticoagulation treatment, or in cases where past contraindicated. Duration of treatment – no more than 3 months. prevention of clotting in the extracorporeal circulation system during hemodialysis in patients undergoing repeated hemodialysis sessions lasting no more than 4 hours, provided there is no risk of bleeding, blood clotting prevention in the extracorporeal blood circulation system dialysis process is achieved by a single dose in the form of a bolus injection into the arterial tree at the beginning of the dialysis session. A single dose for patients weighing less equipose, for patients weighing Correction dose for elderly patients is not required. The data allows us to give recommendations for correction doses of sodium bemiparin for patients with hepatic impairment and kidney are not available. Dosing (technique of subcutaneous injection) syringes ready for immediate use and does not require sterilization. The drug is injected into the subcutaneous layer of the abdomen anterolateral or posterolateral lumbar region (waist), alternately with the right and left sides. The needle is inserted to the full depth perpendicularly (vertically), rather than at an angle in the skin fold formed by the thumb and forefinger. Folds of skin do not straighten, holding it up to completion of the injection. Injection site does not rub!
The most frequently reported side effect is hematoma and / or ecchymosis at the injection site (about 15% of patients).
The long-term heparin therapy can lead to the development of osteoporosis.
The frequency of side effects in the appointment of sodium bemiparin corresponds to that reported for other low molecular weight heparins, and is given below : Very frequent equipose). ecchymosis at the injection site frequent ( > 1/100 <1/10) pain and hematoma at the injection site bleeding (in the skin, mucous membranes, wounds, gastrointestinal tract , urinary tract), a slight transient increase in transaminases and equipose.